x
CME-Tagline

Live Q&A: Signals of Change in the Management of Atopic Dermatitis

CMEO Webcast

Premiere Date: Wednesday, June 23, 2021

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, June 23, 2022

Faculty


Jonathan I. Silverberg, MD, PhD, MPH Jonathan I. Silverberg, MD, PhD, MPH 
Associate Professor of Dermatology
Director of Clinical Research and Contact Dermatitis
George Washington University School of Medicine and Health Sciences
Washington, DC

Statement of Need

Atopic dermatitis (AD) is a chronic, inflammatory skin disease that affects up to 18% of children and up to 10% of adults and can have a substantial negative impact on the quality of life (QoL) of patients and their families. Its management is challenging at any age, with patients and caregivers often becoming overwhelmed by the chronic and relapsing nature of AD. Establishing disease severity is essential to inform treatment decisions, as is information on new clinical trial data for therapies such as oral Janus Kinase (JAK) inhibitors. Thus education that provides tools to establish disease severity and information on the development of new agents is warranted in order to mitigate the clinical and QoL impact of AD.

This live question and answer session is your opportunity to ask questions based on the CME Outfitters virtual symposium where expert faculty focused on applying clinical tools to establish disease severity, translating how new agents will impact clinical practice, and integrating patient preferences and treatment goals into shared decision-making (SDM). To view the full activity ahead of this live Q&A, click here.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Apply clinical tools to establish disease severity to inform treatment decisions in patients with AD.
  • Translate the results of safety and efficacy data from recent clinical trials for emerging agents to the treatment of moderate-to-severe AD.
  • Integrate patient preferences and treatment goals into SDM for moderate-to-severe AD treatment.

The following learning objectives pertain only to those requesting CNE credit:

  • Identify clinical tools to establish disease severity to inform treatment decisions in patients with AD.
  • Translate the results of safety and efficacy data from recent clinical trials for emerging agents to the treatment of moderate-to-severe AD.
  • Explain how to integrate patient preferences and treatment goals into SDM for moderate-to-severe AD treatment.

Financial Support

Supported by an educational grant from Pfizer Inc.

Target Audience

Allergists, dermatologists, PAs, nurse practitioners, nurses, pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hour (0.05 CEUs). Universal Activity Number:
Live: 0376-0000-21-093-L01-P

Type: knowledge-based

Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Credit request forms and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Silverberg reports that he receives grants from Galderma and Pfizer Inc. He is on the speakers bureau for Pfizer Inc.; Regeneron Pharmaceuticals Inc.; and Sanofi. He is a consultant for AbbVie Inc.; Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC; BiomX; Bluefin Biomedicine; Bodewell; Boehringer-Ingelheim; Celgene Corporation; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; Galderma; GlaxoSmithKline; Incyte; Kiniksa Pharmaceuticals; LEO Pharma Inc.; Luna; Menlo Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; and Sanofi.

Noreen Iftikhar, MD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MMQ-112-062321-02